BioNexus Gene Lab (NASDAQ: BGLC) starts 2026 VitaGuard MRD rollout in Southeast Asia

Rhea-AI Filing Summary

BioNexus Gene Lab Corp. reported that it has formally begun the 2026 regional deployment phase of its VitaGuard™ Minimal Residual Disease (MRD) platform. This marks a shift from development-stage technology to operational deployment focused on Southeast Asia.

The company plans to integrate VitaGuard™ into routine oncology workflows at select regional medical hubs during 2026. It expects this phase to support broader commercialization, expand access to longitudinal cancer monitoring, and generate high-frequency molecular data for future AI-assisted oncology initiatives.

The update also notes that by the end of 2025 the company advanced global patent filings, set up its international commercialization structure, pursued recruitment, and planned Southeast Asia market entry with a regional diagnostics partner. Fidelion Diagnostics Pte. Ltd. will serve as the international intellectual property and commercialization vehicle outside Greater China.

Insights

Healthcare technology and commercialization analyst

BioNexus moves VitaGuard from R&D into regional deployment, targeting Southeast Asia oncology workflows in 2026.

BioNexus Gene Lab is transitioning its VitaGuard™ MRD cancer monitoring platform from development into an operational deployment phase focused on Southeast Asia in 2026. The company aims to embed the platform into routine oncology workflows across selected medical hubs, signaling a move toward practical, clinical use.

The strategy includes phased regional deployment, workflow integration with healthcare providers, and using Fidelion Diagnostics Pte. Ltd. as the international intellectual property and commercialization vehicle outside Greater China. By the end of 2025, BioNexus had advanced global patent filings, built an international commercialization structure, and engaged a regional diagnostics partner for Southeast Asia market entry planning.

Actual commercial traction will depend on execution of workflow integration, adoption by oncology centers, and the pace of regional rollout during 2026. Future disclosures may clarify adoption levels and any resulting revenue contribution as the deployment phase progresses.

0001737523false00017375232026-01-282026-01-28iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 28, 2026

BioNexus Gene Lab Corp.

(Exact name of Company as specified in its charter)

Wyoming		001-41750		35-2604830
(State or other jurisdiction		(Commission		(IRS Employer
of Incorporation)		File Number)		Identification Number)

Unit A-28-7, Tower A, Menara UOA Bangsar,

No.5 Jln Bangsar Utama 1,

59000 Kuala Lumpur

(Address of principal executive offices)

Phone: +1 (307) 241-6898

(Company’s Telephone Number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, no par value		BGLC		Nasdaq

Item 8.01 – Other Events

On January 28, 2026, BioNexus Gene Lab Corp. (the “Company”) issued a press release announcing the formal commencement of its 2026 regional deployment phase for the VitaGuard™ Minimal Residual Disease (“MRD”) platform.

The announcement describes the Company’s transition of VitaGuard™ from a development-stage technology into an operational deployment phase focused on Southeast Asia, including initial plans to integrate the platform into routine oncology workflows across select regional medical hubs during 2026. The Company believes this deployment phase is designed to support broader commercialization efforts, expand access to longitudinal cancer monitoring solutions, and generate high-frequency molecular data intended to support future AI-assisted oncology initiatives.

The press release further outlines the Company’s strategic objectives for 2026, including phased regional deployment, workflow integration with healthcare providers, and the use of Fidelion Diagnostics Pte. Ltd. as the Company’s international intellectual property and commercialization vehicle outside Greater China. The Company also disclosed that, by the end of 2025, it completed certain foundational commercialization steps, including advancement of global patent filings, establishment of its international commercialization structure, recruitment efforts, and Southeast Asia market entry planning with a regional diagnostics partner.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statement and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated January 28, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BioNexus Gene Lab Corp.

By:	/s/ Su-Leng Tan Lee
	Su-Leng Tan Lee
	Chief Executive Officer
Date:	February 3, 2026

3

FAQ

What did BioNexus Gene Lab Corp. (BGLC) announce about the VitaGuard MRD platform?

BioNexus Gene Lab announced the formal start of its 2026 regional deployment phase for the VitaGuard™ Minimal Residual Disease platform. This moves VitaGuard from a development-stage technology into an operational deployment phase focused on oncology applications in Southeast Asia.

How will BioNexus (BGLC) deploy VitaGuard in Southeast Asia during 2026?

The company plans a phased regional deployment, integrating VitaGuard™ into routine oncology workflows across select Southeast Asian medical hubs during 2026. The approach emphasizes workflow integration with healthcare providers to bring MRD-based longitudinal cancer monitoring into everyday clinical practice.

What are BioNexus Gene Lab’s 2026 strategic objectives for VitaGuard?

The 2026 objectives include phased regional deployment of VitaGuard™, workflow integration with healthcare providers, and using Fidelion Diagnostics Pte. Ltd. as the international intellectual property and commercialization vehicle for markets outside Greater China, supporting broader commercialization efforts for the MRD platform.

What groundwork did BioNexus (BGLC) complete for VitaGuard commercialization by the end of 2025?

By the end of 2025, BioNexus completed foundational steps such as advancing global patent filings, establishing its international commercialization structure, conducting recruitment efforts, and planning Southeast Asia market entry in collaboration with a regional diagnostics partner to support VitaGuard’s deployment.

How does Fidelion Diagnostics Pte. Ltd. fit into BioNexus Gene Lab’s VitaGuard strategy?

Fidelion Diagnostics Pte. Ltd. will serve as BioNexus Gene Lab’s international intellectual property and commercialization vehicle outside Greater China. It is intended to hold and commercialize VitaGuard™-related rights in international markets as the MRD platform moves into broader deployment.

How does the VitaGuard deployment support BioNexus Gene Lab’s AI-assisted oncology plans?

The deployment is expected to generate high-frequency molecular data from longitudinal cancer monitoring. BioNexus believes this data will support future AI-assisted oncology initiatives by providing rich, ongoing molecular information from patients monitored through the VitaGuard™ MRD platform.